Observational study finds semaglutide associated with 40% reduction in asthma attacks — Evidence Review

Semaglutide, a diabetes and weight loss medication, was linked to nearly 40% fewer asthma attacks in people with asthma, according to new research from the National Heart & Lung Institute, Imperial College London presented at the European Respiratory Society Congress. Related studies largely agree with these findings, showing GLP-1 receptor agonists may reduce respiratory risks in people with diabetes, obesity, or lung disease.

• Several systematic reviews and meta-analyses have found that GLP-1 receptor agonists, including semaglutide, are associated with lower risks of various respiratory diseases and exacerbations, supporting the new study’s observations in asthma and COPD patients 1 5.
• Observational and meta-analytic research suggests the respiratory benefits of GLP-1 receptor agonists are consistent across multiple patient populations, though some studies note the need for more rigorous prospective trials before recommending these drugs specifically for lung disease 1 4 5.
• Other large-scale cohort and review studies have mapped a broad spectrum of health outcomes for GLP-1 receptor agonists, including reductions in certain respiratory complications, but highlight the importance of monitoring for adverse effects and the necessity for more targeted respiratory outcome trials 2 4.

Study Overview and Key Findings

Asthma and chronic obstructive pulmonary disease (COPD) are common comorbidities in individuals with obesity and type 2 diabetes, yet most clinical trials of metabolic medications have not directly measured lung health outcomes. Recognizing a gap in evidence, researchers from the National Heart & Lung Institute at Imperial College London analyzed real-world health records to examine whether GLP-1 receptor agonists, and semaglutide in particular, might offer protective benefits against acute respiratory events in people already prescribed these drugs for metabolic conditions. Their findings, presented at the European Respiratory Society Congress, suggest that semaglutide use is associated with a notable reduction in asthma attacks and COPD flare-ups compared to other diabetes medications.

Property	Value
Organization	National Heart & Lung Institute, Imperial College London, UK
Authors	Professor Chloe Bloom, Dr. Bohee Lee
Population	People with asthma or COPD
Sample Size	20,000 to 22,000 participants
Methods	Observational Study
Outcome	Asthma attacks, COPD flare-ups
Results	Semaglutide linked to nearly 40% fewer asthma attacks.

Literature Review: Related Studies

To situate the new findings in the broader research landscape, we searched the Consensus database, which includes over 200 million scientific papers. The following search queries were used to identify relevant literature:

1. semaglutide asthma attack reduction
2. Ozempic Wegovy asthma outcomes
3. GLP-1 agonists respiratory health effects

Summary Table of Related Study Topics and Findings

Topic	Key Findings
How do GLP-1 receptor agonists affect respiratory disease risk and exacerbations?	- GLP-1 receptor agonists, including semaglutide, are associated with reduced risk of respiratory diseases and exacerbations 1 5.
	- Multiple studies show significant reductions in asthma and COPD flare-ups among GLP-1RA users compared to sulfonylureas or DPP-4 inhibitors 5.
Are the respiratory benefits of GLP-1RAs consistent across different populations and comparators?	- Benefits are observed in adults with type 2 diabetes and comorbid obstructive lung diseases, but comparisons vary by control group 1 5.
	- Some studies note a stronger effect compared to sulfonylureas/DPP-4 inhibitors but not always versus SGLT2 inhibitors or metformin 5.
What are the broader health outcomes and safety considerations for GLP-1RA use?	- GLP-1RAs are linked to reduced risks of several non-respiratory conditions but may increase the likelihood of gastrointestinal and other adverse events 2 4.
	- Umbrella reviews highlight trends toward improved respiratory outcomes but also emphasize methodological limitations and the need for further research 4.
What is the current evidence gap and need for future research on GLP-1RAs and respiratory health?	- Most studies are observational; high-quality randomized trials with respiratory endpoints are needed to determine causality 4 5.
	- There is support for including respiratory outcomes in future metabolic therapy trials 2 4 5.

How do GLP-1 receptor agonists affect respiratory disease risk and exacerbations?

Recent meta-analyses and observational studies consistently report that GLP-1 receptor agonists reduce the risk of respiratory illnesses, including asthma attacks and COPD exacerbations, particularly in individuals with type 2 diabetes and obesity. The new study aligns closely with these findings, especially regarding semaglutide's notable effects.

• Meta-analyses show a statistically significant reduction in respiratory disease risk (up to 18% lower with semaglutide) among GLP-1RA users compared to controls 1.
• GLP-1RA use is associated with reduced rates of asthma and COPD flare-ups, with pooled incidence rate ratios favoring GLP-1RA over sulfonylureas or DPP-4 inhibitors 5.
• The new observational study's 40% reduction in asthma attacks with semaglutide is consistent with prior findings, though somewhat higher than pooled estimates in earlier analyses 1 5.
• There is emerging recognition of potential pulmonary protective effects of GLP-1RAs in patients with metabolic comorbidities 1 5.

Are the respiratory benefits of GLP-1RAs consistent across different populations and comparators?

The evidence suggests that GLP-1RAs' respiratory benefits are most pronounced when compared to certain diabetes medications, but results may vary depending on the comparator and population. The current study and related reviews highlight variation in effect size.

• Benefits are greater when GLP-1RA users are compared to those taking sulfonylureas or DPP-4 inhibitors, but less clear when compared with SGLT2 inhibitors or metformin 5.
• Observational analyses include diverse populations but often focus on those with both diabetes and obstructive lung disease 1 5.
• The new study’s finding of a strong effect for semaglutide in asthma is consistent with subgroup findings from previous systematic reviews 1 5.
• Differences in control groups and baseline risk factors may influence observed effect sizes in both new and existing studies 5.

What are the broader health outcomes and safety considerations for GLP-1RA use?

While GLP-1RAs are associated with potential benefits for respiratory as well as metabolic, cardiovascular, and cognitive outcomes, the class is also linked to increased risks for certain adverse events. Systematic reviews urge careful patient selection and monitoring.

• Large-scale outcome mapping studies report lower risks of psychotic, neurocognitive, and infectious illnesses, as well as some respiratory conditions, in GLP-1RA users compared to usual care 2.
• However, higher risks of gastrointestinal events, hypotension, syncope, and other adverse events are also noted, indicating a need for balanced risk-benefit assessment 2 4.
• Umbrella reviews highlight a trend toward improved respiratory outcomes but point out methodological limitations in the evidence base 4.
• The new study did not focus on adverse events, emphasizing the importance of future research on both efficacy and safety 4.

What is the current evidence gap and need for future research on GLP-1RAs and respiratory health?

Despite promising findings, most existing data on GLP-1RAs and respiratory outcomes are drawn from observational studies or post-hoc analyses. There is broad consensus that prospective, randomized trials with respiratory endpoints are necessary.

• Systematic reviews call for randomized controlled trials to confirm associations and clarify causality for respiratory benefits 4 5.
• There is support for including lung health outcomes in future trials of metabolic therapies, acknowledging the interconnections between metabolic and respiratory disease 2 4 5.
• Methodological shortcomings, such as bias and incomplete reporting in existing studies, limit definitive conclusions 4.
• The new study adds to the evidence base but does not provide grounds to recommend GLP-1RA therapy for lung disease outside current guidelines 4 5.

Future Research Questions

While observational and meta-analytic data suggest respiratory benefits for GLP-1RA users, particularly those taking semaglutide, further research is required to confirm these associations, understand mechanisms, and guide clinical practice. Key areas for future investigation include prospective trials, comparative effectiveness, and safety monitoring.

Research Question	Relevance
Do GLP-1 receptor agonists reduce asthma attacks in non-diabetic patients with asthma?	Most existing studies focus on patients with diabetes; it is unclear whether the benefits extend to non-diabetic asthma populations 1 5.
Are the respiratory benefits of semaglutide superior to other GLP-1 receptor agonists?	The current study suggests a particularly strong effect for semaglutide, raising questions about differential efficacy within the drug class 1 5.
What are the mechanisms by which GLP-1RA therapy affects lung inflammation and function?	Understanding biological pathways could inform targeted therapies and optimize benefit-risk profiles for respiratory disease management 1 4.
What are the long-term respiratory and systemic safety outcomes of GLP-1 receptor agonists?	Safety profiles, including rare adverse events, need further exploration in large, long-term studies to ensure patient safety 2 4.
Should respiratory outcomes be included as primary endpoints in future trials of metabolic therapies?	Given the emerging evidence for cross-system benefits, future trials may need to systematically incorporate respiratory endpoints to inform clinical guidelines 2 5.